FDA Grants Breakthrough Therapy Designation to Merck’s Sacituzumab Tirumotecan for EGFR-Mutated NSCLC

Spur Therapeutics Unveils SPR301: A Novel Gene Therapy for GBA1-Linked Parkinson’s Disease

M | O | C Cancer Care & Research Centre Achieves CAR-T Therapy Milestone

Aptose Biosciences Collaborates with NCI to Advance Tuspetinib in Precision Medicine Trials for AML and MDS

Novartis and PTC Therapeutics Forge $2.9 Billion Partnership for Huntington’s Drug PTC518

HCG and Accenture Partner to Transform Cancer Care with Advanced AI

GE HealthCare to Acquire Full Ownership of Nihon Medi-Physics, Expanding Molecular Imaging Leadership in Asia

Strand Life Sciences Unveils CancerSpot for Early Cancer Detection

Allink Biotherapeutics Secures $42 Million in Series A Financing to Accelerate Development of Next-Generation Oncology and Immunology Therapies

Apollo Cancer Centres Launch India’s First Lunglife Screening Programme for Early Detection of Lung Cancer

Agilus Diagnostics Unveils Claudin 18.2 Test: A Breakthrough in Cancer Care

Leqembi® Launched in South Korea for Early Alzheimer’s Disease Treatment

QIAGEN Expands QIAstat-Dx Operations with New Facility in Barcelona

SunAct Cancer Institute Partners with Abgentil Biomedical to Revolutionize Cancer Treatment in India

Dr. Reddy’s Launches Toripalimab in India for Advanced Nasopharyngeal Carcinoma

Home
/
update
/
details

HCG and Accenture Partner to Transform Cancer Care with Advanced AI

NextEdge Admin

03 Dec 2024

2 min 14 sec

HealthCare Global Enterprises (HCG) has partnered with Accenture to revolutionize cancer research and care using advanced AI, including generative AI and deep learning, to analyze multi-dimensional and multi-omic patient data. This collaboration merges Accenture’s global expertise in AI/ML, generative AI, and quantum computing with HCG’s clinical insights in oncology, aiming to advance early cancer detection and treatment.

Accenture will employ cutting-edge technologies such as image analysis, informatics, and novel algorithms to study molecular alterations in cancer patients, enhancing care and fostering groundbreaking research. Leveraging Accenture’s generative AI studios, the initiative seeks to identify new drug targets, mechanisms, pathways, and biomarkers, driving innovation in cancer therapeutics.

Initially focusing on lung adenocarcinoma and head and neck cancers, the program will expand to other cancer types. It aims to identify molecular signatures for prognosis and therapeutic response, enabling personalized treatment strategies. By integrating AI, cloud computing, and machine learning, the collaboration will enhance the understanding of cancer development and improve precision medicine approaches.

Dr. B.S. Ajaikumar, HCG’s executive chairman, emphasized the critical role of AI in addressing tumor heterogeneity and advancing personalized therapies, while Accenture’s global data and AI lead, Senthil Ramani, highlighted the transformative potential of next-generation computing in cancer care. This South Asia-first initiative underscores the commitment of both organizations to innovation, improving patient outcomes, and shaping the future of oncology research and treatment globally.